Injectable BMSC-Based Extracellular Matrix-Mimicking Microtissue for Myocardial Infarction Repair

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Cardiovascular Research

Background:

• Myocardial infarction (MI) alters the cardiac microenvironment, hindering bone marrow-derived mesenchymal stem cell (BMSC) efficacy.
• Limited in vivo differentiation and survival of BMSCs restrict their therapeutic potential after MI.

Purpose of the Study:

• To develop an injectable biomimetic microtissue system (JLSV-BMSC) to support BMSC function in the post-MI cardiac environment.
• To evaluate the in vitro and in vivo therapeutic potential of the JLSV-BMSC microtissue for MI treatment.

Main Methods:

• Fabrication of a dual biomimetic scaffold (Janus Basic Nanotubes, laminin, SDF-1α, VEGF) for BMSC encapsulation.
• In vitro assessment of BMSC survival, migration, proliferation, and paracrine signaling under hypoxic conditions.
• In vivo evaluation of JLSV-BMSC microtissue in a myocardial infarction model, assessing cell retention, differentiation, cardiac remodeling, and function.

Main Results:

• The JLSV-BMSC microtissue significantly enhanced BMSC survival, proliferation, migration, and anti-apoptotic capacity in vitro.
• In vivo studies demonstrated improved BMSC retention, directed differentiation into cardiomyocytes and endothelial cells, reduced fibrosis and apoptosis, and promoted angiogenesis.
• The treatment led to improved cardiac remodeling and functional recovery after myocardial infarction.

Conclusions:

• The JLSV-BMSC microtissue represents a promising strategy to overcome limitations in current stem cell-based therapies for myocardial infarction.
• This biomimetic system effectively mimics the myocardial microenvironment, supporting BMSC therapeutic potential and improving cardiac outcomes.